Yohei Mikami

Associate Professor

Keio University School of Medicine

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Yohei Mikami is an Associate Professor at the School of Medicine, Keio University in Japan. His research primarily focuses on immunology and inflammatory bowel diseases, as evidenced by his recent publications on topics such as epigenomic control of immunity and the metabolic effects of maternal circadian rhythms. Additionally, he investigates the genetic aspects of COVID-19 and the roles of various cytokines in immune cell differentiation.

Articles (18)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Natural killer (NK) cells and type 1 innate lymphoid cells (ILC1) require signal transducer and activator of transcription 4 (STAT4) to elicit rapid effector responses and protect against pathogens. By combining genetic and transcriptomic approaches, we uncovered divergent roles for STAT4 in regulating effector differentiation of these functionally related cell types. Stat4 deletion in Ncr1 -expressing cells led to impaired NK cell terminal differentiation as well as to an unexpected increased generation of cytotoxic ILC1 during intestinal inflammation. Mechanistically, Stat4 -deficient ILC1 exhibited upregulation of gene modules regulated by STAT5 in vivo and an aberrant effector differentiation upon in vitro stimulation with IL-2, used as a prototypical STAT5 activator. Moreover, STAT4 expression in NCR + innate lymphocytes restrained gut inflammation in the dextran sulfate sodium-induced colitis model limiting pathogenic production of IL-13 from adaptive CD4 + T cells in the large intestine. Collectively, our data shed light on shared and distinctive mechanisms of STAT4-regulated transcriptional control in NK cells and ILC1 required for intestinal inflammatory responses.

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (88)

Xavier Farré Ramon

Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol

SPAIN

Yohei Mikami

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

Epigenomic Control of Immunity: From Mechanisms to Therapeutic Targets in Inflammatory Bowel Diseases.

Maternal circadian rhythms during pregnancy dictate metabolic plasticity in offspring.

A CTCF-binding site in the Mdm1-Il22-Ifng locus shapes cytokine expression profiles and plays a critical role in early Th1 cell fate specification.

A second update on mapping the human genetic architecture of COVID-19.

Divergent roles for STAT4 in shaping differentiation of cytotoxic ILC1 and NK cells during gut inflammation

Network Approaches to Uncover Pathogenesis and Therapeutic Targets of Inflammatory Bowel Diseases.

Microbial ligand-independent regulation of lymphopoiesis by NOD1.

DOCK2 is involved in the host genetics and biology of severe COVID-19

Characteristics of adult patients newly diagnosed with Crohn's disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn's disease in Japan (iCREST-CD).

Aryl hydrocarbon receptor signals in epithelial cells govern the recruitment and location of Helios<sup>+</sup> Tregs in the gut.

Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis.

Mapping the human genetic architecture of COVID-19.

Cholesterol 25-hydroxylase is a metabolic switch to constrain T cell-mediated inflammation in the skin.

Epithelium Replacement Contributes to Field Expansion of Squamous Epithelium and Ulcerative Colitis-Associated Neoplasia.

MicroRNA-directed pathway discovery elucidates an miR-221/222-mediated regulatory circuit in class switch recombination.

Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver.

Vagus nerve-mediated intestinal immune regulation: therapeutic implications for inflammatory bowel diseases.

MicroRNA-221 and -222 modulate intestinal inflammatory Th17 cell response as negative feedback regulators downstream of interleukin-23.

Collaborators (88)

Xavier Farré Ramon

Pär Ingemar Johansson

Andrea Ganna

Mario Caceres

Elżbieta Kaja

Edith Nutescu

Yoshihiro Eriguchi

Steven Jones

Justine Rudkin

André G Uitterlinden

Silvano Sozzani

Mattia Cordioli

Louise MacGillivray

Markus Nöthen

Sarah Earle

MITSUHIRO YAMADA

Stuart Turvey

Yuji Yamamoto

Hyeongseok Jeong

James Furniss

David Ellinghaus

Mari Kaunisto

Rosanna Asselta

Vincenzo Forgetta

Anthony Rostron

Shawneequa Callier

Alessio Gerussi

Nirmal Vadgama

Petros Andrikopoulos

Eamon Raith

José Manuel Soria Fernández

Philip Jansen

David Morrison

Yasser El-Sherbiny

Ida Moltke

Barbara Shih

Junichi Sasaki

Minttu Marttila

Caroline Cusick

Giuseppe Sciumè

Shea Andrews

Mathias Van Singer

Paul Dark

Khoa Manh Dinh

Yusuke Kawamura

Akiyoshi Nakayama

Kate H. Moore

Takahito Fukusumi

Marielle LEBRUN

Jörg Hamann

Gabriella Lindergard

Giovanni BERNARDINI

Tomomi Takano

Marc Moritz Berger

Sandor Szalma